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Abstract
Background—Fibrosis progression in hepatitis C virus (HCV)-infected patients varies greatly 
between individuals. Chemokines recruit immune cells to the infected liver and may thus play a 
role in the fibrosis process.
Aim—To investigate plasma levels of a diverse chemokine panel in relation to liver fibrosis.
Methods—African-American and Caucasian HCV genotype 1 infected patients were treated with 
peginterferon (pegIFN) and ribavirin (RBV) for 48 weeks (VIRAHEP-C cohort). Plasma levels of 
13 cytokines were studied at baseline (n=386). Subsequently, GROα levels were assessed in a sub 
cohort (n=99) at baseline, and at 4 and 12 weeks after start of pegIFN/RBV treatment.
Results—Increased severity of fibrosis (Ishak fibrosis score 0–2 versus 3–6) was associated with 
increased plasma IP-10 (CXCL10) and IL-8 (CXCL8) levels, and decreased plasma levels of the 
chemokine growth-related oncogene (GRO, CXCL1-3). Plasma GRO levels were also positively 
correlated with platelet counts, and were higher in African-American as compared to Caucasian 
patients. In response to pegIFN/RBV treatment, GROα levels increased in Caucasian but not 
African-American patients from week 4 onwards.
Conclusion—The association with severity of fibrosis and platelet count positions plasma GRO 
as a potential biomarker for liver fibrosis in HCV-infected patients. The secretion of GRO by 
platelets may explain the correlation between GRO plasma level and platelet count. The ethnic 
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difference in GRO levels both pre-treatment and in response to pegIFN/RBV might be driven by a 
genetic polymorphism in GROα associated with higher plasma levels and more common in the 
African-American population.
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Introduction
Hepatitis C virus (HCV) is a blood-borne virus, infecting approximately 170 million people 
in the world. HCV establishes a chronic infection in the liver in about 80% of individuals 
infected. The severity of the disease can vary from asymptomatic chronic infection to liver 
fibrosis and cirrhosis that can result in hepatocellular carcinoma or liver failure 1. The rate of 
progression from an early stage of fibrosis to cirrhosis varies greatly between individuals 
and is known to be influenced by duration of HCV infection, alcohol consumption and HIV 
or HBV co-infection 2.
Liver fibrosis is defined as an accumulation of extracellular matrix proteins and a modified 
liver architecture. Specialized liver macrophages called Kupffer cells react on viral 
infections by producing chemoattractants for lymphocytes (i.e. chemokines) and by 
activating hepatic stellate cells that start to produce excess extracellular matrix proteins 3. 
Both the recruited lymphocytes and the hepatic stellate cells secrete pro-inflammatory 
cytokines and chemokines, leading to a low-grade inflammation that may cause tissue 
damage. These chemokines and cytokines together with extracellular matrix proteins are 
important mediators of liver fibrosis progression, since increased expression of chemokines 
and cytokines in the liver and peripheral blood has been reported in relation to progressive 
liver fibrosis and cirrhosis 3, 4.
Over the last decade, HCV-infected patients have been treated with peginterferon (pegIFN) 
and ribavirin (RBV), which results in 40–50% sustained virological response (SVR) in HCV 
genotype 1 infected patients 5. The treatment response rate in patients of different ethnicities 
is known to vary, which is especially true for African-American patients showing a lower 
SVR rate as compared to Caucasian patients 6. Although not fully understood this may at 
least partially be attributed to genetic polymorphisms, such as the rs12979860 
polymorphism in the promoter region of the IL28B gene that is associated with SVR to 
pegIFN/RBV therapy 7.
Ethnicity may also influence the outcome of the HCV-related liver disease. A lower rate of 
cirrhosis has been reported in African-American patients as compared to other ethnicities in 
some studies 8, 9. Here we investigated factors contributing to a more severe fibrosis in the 
Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (VIRAHEP-C) cohort 
that was set up to identify factors that determine why African-Americans infected with HCV 
genotype 1 respond less well to therapy with pegIFN/RBV compared to Caucasians 6. The 
primary aim of the study was to investigate if plasma levels of certain chemokines are 
associated with the liver fibrosis stage in HCV-infected patients. Multiple chemokines and 
cytokines were assessed in peripheral blood and their association with liver fibrosis was 
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analyzed in concert with clinical characteristics and blood parameters routinely determined 
in HCV-infected patients. We report on a novel association for the neutrophil recruiting 




The VIRAHEP-C study is a multicenter study of pegIFN/RBV therapy in African-American 
and Caucasian patients with HCV genotype 1 infection 6. Only patients that classified 
themselves by ethnicity as either African-American or Caucasian American were included. 
Patients also needed to be aged between 18 and 70 years, be treatment naïve, and have 
detectable HCV RNA and histologic evidence of chronic HCV. The study enrolled 401 
patients from eight clinical centers in the United States and pegIFN/RBV therapy started 
between July 2002 and December 2003. Patients were treated with 180μg pegylated 
interferon α-2a (Pegasys, Roche Pharmaceuticals, Nutley, NJ) per week and 1000–1200 mg 
RBV (Copegus, Roche Pharmaceuticals, Nutley, NJ) per day for up to 48 weeks. All 
participants provided written informed consent, including consent for genetic testing.
Baseline blood assessments
Blood counts, including platelet count, and serum levels of alanine transaminase (ALT), 
total bilirubin, albumin, ferritin, fasting triglycerides, hematocrit and hemoglobin were 
assessed at the local clinical laboratories. HCV RNA testing was done as previously 
reported 6. The IL28B polymorphic marker rs1297860 was genotyped in 297 patients who 
consented for genetic analysis, as described earlier 10.
Liver histology
All patients had undergone liver biopsy within 18 months of screening and the biopsies were 
graded as previously described 11, 12. Necroinflammatory changes were graded from 0 to 18 
according to the histologic activity index (HAI), which is the sum of periportal necrosis (0–
10), lobular inflammation (0–4) and portal inflammation (0–4). A HAI score of more than 8 
means that the inflammation is moderate or marked. Fibrosis was graded from 0 to 6 
according to the ISHAK fibrosis scale, where a fibrosis score of 3 or more was regarded as 
severe fibrosis in accordance with a previous study from the VIRAHEP-C cohort 11. 
Steatosis was graded depending on percentage of cells with fat from 0 to 4, where 1 equals ≥ 
5%.
Plasma cytokine quantification
Plasma samples from 386 patients from the VIRAHEP-C cohort were available for analysis 
at baseline (Table 1). Milliplex human cytokine/chemokine panel I, II and III assays 
(Millipore) were used to assess plasma levels of 13 cytokines and chemokines, including 
GRO, interleukin 8 (IL-8), IL-6, IL-9, IL-10, IL-18, IL-29, IL-28a, IFN-γ, MIG, I-TAC, 
SDF-1a/b and MIP-1β. Each sample was analyzed in duplicate and at least three control 
samples were included on each plate to assess possible plate effects and inter-assay 
variability. Duplicate samples that varied much were rerun if samples were available. Intra- 
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and inter-assay variability was calculated for each reliably measured individual analyte. 
BioPlex Manager 6.1 software was used to generate the standard curves for each analyte and 
derive protein concentrations in each sample. Plasma interferon gamma-induced protein 10 
(IP-10, CXCL10) levels (Quantikine human IP-10 assay from R&D systems) in the 
VIRAHEP-C cohort that were determined and reported previously 10 were also included in 
the data analysis of this study.
A smaller sub cohort of 99 patients, comprising 49 SVR and 50 non-SVR patients, with 
similar numbers of Caucasian and African-American patients in each response group, were 
included in a sub cohort for on-therapy assessment of GROα (CXCL1) (Table 1). Plasma 
expression levels of GROα in samples collected at baseline, and at 4 and 12 weeks after start 
of treatment were derived from analyses using a human 7 cytokines BioPlex assay (Bio-
Rad).
Statistical analysis
Cytokine concentrations and blood parameters that were not adhering to normal distribution 
were log-transformed before statistical testing. Standard statistical analyses were performed 
in R (version 3.0.1), using publicly available packages. For the univariate analyses of single 
variables, statistical tests included t-test, paired t-test, Chi-squared test, ordinary linear 
regression, ANOVA, Tukey’s honest significance test and Pearson correlation. The 
Bonferroni method was applied to correct for multiple comparisons and the cut-off for a 
statistically significant test was set at p≤0.01. Generalized linear binomial models and linear 
models were used for multivariate prediction of categorical variables and continuous 
variables, respectively. Step-wise selection (upwards and downwards) was performed with a 
cut-off of p≤0.01 for a variable to be included in the final model. A mixed model was used 
to assess differences in change over time for different patient groups.
Results
Multiplex plasma cytokine analysis in HCV patients
In total 386 patients from the VIRAHEP-C study were included in the investigation of 
cytokine plasma levels in untreated HCV patients. Baseline patient characteristics for the 
cohort are shown in Table 1. Thirteen cytokines were selected based on literature findings 
and biological associations and the plasma concentrations of these were investigated by 
multiplex protein assays. Eight of these cytokines could be reliably measured at baseline: 
GRO (CXCL1, CXCL2, CXCL3), IL-8 (CXCL8), MIP-1β (CCL4), IL-18, MIG (CXCL9), 
SDF-1a/b (CXCL12), I-TAC (CXCL11) and IL-29 (IFNλ1). The other cytokines in the 
multiplex assay (IFN-γ, IL-6, IL-9, IL-10 and IL-28a) were found out of range and have 
been excluded from further analyses because the large majority (55–91%) of the samples 
had concentrations below the detection limit. The intra-assay variability for the reliably 
measured analytes were 3.2 % for GRO, 3.7% for MIG, 4.7% for IL-18, 4.8% for IL-8 and 
MIP-1β, 5.0% for SDF-1a/b, 5.3% for I-TAC and 7.9% for IL-29. Similarly the inter-assay 
variability varied between 4.5 and 7.0%.
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Association of GRO, IL-8 and IP-10 with ISHAK fibrosis score
Potential associations of cytokine levels with fibrosis severity were assessed by comparing 
patients with high (≥3) versus low (<3) ISHAK fibrosis score. We also included gender, 
ethnicity, and other measured baseline blood parameters in this analysis. Eight out of the 23 
variables in the analysis were significantly associated with severe fibrosis after correction 
for multiple comparisons (Table 2). The chemokines IP-10, GRO and IL-8 were statistically 
significantly different in patients with a high ISHAK fibrosis score compared to those with a 
low score. The other variables in the analysis found to be associated with fibrosis (platelet 
count, age, ALT, bilirubin and ferritin) were identified and reported earlier in the 
VIRAHEP-C cohort 11. When including all significant variables in a multivariate 
generalized linear model, only platelet count (p=6×10−6) and ALT levels (p=0.008) appear 
to significantly contribute to the model explaining severe versus non-severe fibrosis.
Plots of the plasma IP-10, GRO and IL-8 levels in function of ISHAK scores (0, 1–2, 3–4 
and 5–6) show increasing levels of IP-10 and IL-8 and decreasing levels of GRO with higher 
ISHAK score (Figure 1). Whereas the association between increased peripheral IP-10 levels 
and more severe fibrosis is well established in the literature 13, 14, the relationship between 
fibrosis and GRO or IL-8 is much less investigated. Therefore, we focused our further 
analyses on GRO and IL-8, which share the possibility to bind the CXCR2 receptor that is 
expressed on neutrophils.
Association of GRO with ethnicity and platelet count
The association between GRO or IL-8 and various patient parameters connected to liver 
disease were assessed. Factors associated with IL-8 in univariate analyses were albumin, 
HAI inflammation and ISHAK fibrosis score (Supplementary Table), however in a 
multivariate analysis none of the variables were good predictors for plasma levels of IL-8 
(data not shown). In a univariate analysis of associations between GRO plasma levels and 
baseline parameters measured in the HCV-infected patients the variable most strongly 
associated with GRO was ethnicity (Table 3). Indeed, African-American patients had higher 
plasma GRO levels as compared to Caucasian patients (Supplementary Figure A). GRO was 
also significantly associated with the blood parameters platelet count, ALT levels, bilirubin, 
hemoglobin and the liver biopsy parameters for fibrosis (ISHAK) and inflammation (HAI) 
(Table 3 and Supplementary Figure). Multivariate linear regression modeling to predict 
GRO plasma levels revealed a model with significant contributions of ethnicity 
(p=2.2×10−16) and platelet count (p=2.3×10−9). Although there was no significant 
interaction between ethnicity and platelet count in prediction of GRO levels (p=0.087), a 
trend towards a stronger correlation between GRO and platelet count was observed in 
Caucasian (r=0.58) as compared to African-American patients (r=0.34) (Figure 2).
High GROα levels in African-Americans
A polymorphism in the GROα (CXCL1) gene has been associated with higher plasma levels 
of GROα 15 and this polymorphism is more common in the African-American population 16. 
Since the antibody used in the analysis of the whole cohort bound three proteins, GROα 
(CXCL1), β (CXCL2), γ (CXCL3), we investigated if our association between ethnicity and 
GRO levels would be seen in a GROα specific assay in a sub cohort from the VIRAHEP-C 
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study. This sub cohort included 99 patients and was representative of the patients in the 
whole cohort (Table 1). Our results confirm that the GROα levels were significantly higher 
in African-American versus Caucasian patients (p=4×10−13).
Increased GROα levels in response to pegIFN/RBV treatment in Caucasians
To investigate whether GROα levels are affected by pegIFN/RBV treatment, plasma levels 
at week 4 and week 12 after the start of treatment were also assessed in the sub cohort of 99 
patients. During the first 4 weeks of treatment with pegIFN/RBV, GROα levels increased in 
Caucasian but not in African-American patients (Figure 3). However, GROα levels did not 
further change between week 4 and week 12 after start of treatment. The interaction between 
ethnicity and time was highly significant (p=1.9×10−7) in a mixed model comparing subject-
specific time profiles. Of note, the GROα response to pegIFN/RBV treatment did not differ 
between patients that achieved SVR and those that did not, or between patients with a low 
(<3) or high (≥3) ISHAK score (data not shown).
Discussion
Plasma levels of three chemokines associated significantly with liver fibrosis in the 
VIRAHEP-C cohort. This is to our knowledge the first report associating lower plasma 
GRO levels with fibrosis in HCV-infected patients, while the higher peripheral levels of 
IP-10 and IL-8 in HCV-infected patients with severe fibrosis confirm earlier 
reports 13, 14, 17, 18. Many chemokines are up-regulated in the infected liver in response to 
the HCV virus and the pro-inflammatory milieu, where they are involved in regulating 
inflammation, fibroproliferation and angiogenesis 4. The role and significance of altered 
levels of chemokines in peripheral blood of HCV infected patients is, however, less well 
understood. They may be byproducts of the excess production in the inflamed liver or have a 
regulatory function, either by mediating a gradient for leukocyte recruitment or by inducing 
downregulation of chemokine receptors on leukocytes in the periphery. Irrespective of their 
functional role in the periphery, it seemed reasonable to explore whether peripheral 
chemokines may serve as biomarkers reflecting the fibrosis stage in the liver of HCV-
infected patients 4.
IP-10, IL-8 and GRO all belong to the CXC chemokine family. IP-10 (CXCL10) and the 
two related chemokines MIG (CXCL9) and I-TAC (CXCL11) are induced by Th1 
cytokines, bind the CXCR3 receptor and recruit T cells. IL-8 (CXCL8) and GRO proteins 
are homologous for only about 40%, but they both bind to the CXCR2 receptor and recruit 
neutrophils. However, IL-8 can in addition also bind the CXCR1 receptor 19. The three 
GRO proteins, GROα (CXCL1), β (CXCL2) and γ (CXCL3) are close homologs, with an 
amino acid similarity of approximately 90 % 20. GRO proteins are produced by monocytes 
and neutrophils, and differences in the upstream regulatory region of the GRO encoding 
genes may result in diverse cell type expressions 20. GROα can be produced by liver cells, 
like hepatocytes and hepatic stellate cells, upon stimulation with IL-1α, TNF or IL-17 21, 22. 
Expression of GRO is also induced by TLR signaling 23. The HCV antigens HCV core and 
NS3 signal through TLR2 and Nischalke et al showed that these HCV antigens induce 
secretion of GROα in monocytes from whole blood 15.
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The increased levels of both IP-10 and IL-8 in patients with more severe fibrosis have been 
suggested to promote liver damage. In HCV-infected livers IP-10 secretion is induced by 
virus activation of pathogen recognition receptors and by increased levels of type I 
interferons 4. The elevated levels of IP-10 and the other CXCR3 binding chemokines in the 
liver of HCV-infected patients 13, 24, 25 attracts CXCR3+ cells from the periphery, most of 
them not HCV-specific, and these inflammatory cells can cause damage to the surrounding 
tissue and could lead to fibrosis 25, 26. The levels of IL-8 are also increased in the liver of 
HCV-infected patients 27, 28. IL-8 is secreted by neutrophils recruited to the liver in response 
to the viral infection and can also be induced by the HCV virus 4. IL-8 may recruit 
neutrophils, monocytes and macrophages to the liver, and the enhanced presence of 
macrophages has been correlated with increased severity of fibrosis in liver disease 
patients 29. However, our finding that IL-8 is only weakly associated with liver damage 
parameters in HCV-infected patients is in line with findings from other studies 29, 30.
The opposite directions of the association with liver fibrosis score for peripheral GRO 
versus IL-8 levels may suggest that these chemokines have different functions during the 
progression of fibrosis. Peripheral GROα levels are increased in HCV infected patients as 
compared to healthy individuals 18 and this may be due to HCV-induced secretion of 
GROα 15. However, only one other research group has reported on peripheral GRO levels 
related to fibrosis in HCV-infected patients. Costantini et al found similar serum levels of 
GROα in cirrhotic and non-cirrhotic HCV-infected patients 18, 31. The relatively small 
numbers of patients in these studies and the GROα analysis that was performed in serum 
instead of plasma samples might have led to different results as compared to our study. 
Indeed, the latter could influence the results since activated platelets may release pre-stored 
chemokines, including GRO, upon collection of serum in tubes 32. Interestingly, elevated 
GROα mRNA levels in the liver have been reported in HCV-infected patients with severe 
fibrosis 15, 27. Also in mice models do increased GROα levels in the liver coincide with the 
onset of liver fibrosis 33. We hypothesize that this together with our reported decrease in 
peripheral GRO levels reflect a chemokine gradient favoring recruitment of GRO-binding 
leukocytes out of the liver during early phases of fibrosis and into the liver in patients with 
more severe fibrosis. If so, higher GRO levels in the periphery might serve as a protection 
against further progression of fibrosis. Additional studies with paired liver biopsy and 
plasma samples from HCV-infected patients are necessary to discern this potential 
mechanism further. Also, in order to assess whether GRO is involved in the progression of 
fibrosis, the chemokine should be analyzed in a cohort of patients with the same fibrosis 
stage but with different fibrosis progression rates.
The finding that GRO plasma levels correlate with platelet count, the factor most strongly 
associated with severe fibrosis in our cohort, strengthens the picture of GRO as a marker for 
fibrosis stage. Indeed, platelet count as well as liver transaminase levels (ALT and aspartate 
transaminase (AST)) are known biomarkers of liver fibrosis and cirrhosis 34, and the 
multivariate model generated previously aiming to predict severe fibrosis in the VIRAHEP-
C cohort included platelet count, in addition to AST, age and alkaline phosphatase 11. 
GROα is stored in platelet granules and can be secreted upon activation 32, 35. The decrease 
in GRO plasma levels in patients with more severe fibrosis might therefore at least partially 
reflect a reduced number of blood platelets (thrombocytopenia) in these patients. Apart from 
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the thrombocytopenia itself, also other mechanisms could underlie the correlation between 
plasma GRO levels and platelet counts in chronically HCV-infected patients. The platelet 
growth factor thrombopoietin can induce GRO production by megakaryocytes and stimulate 
platelet activation and granule release 36, 37. As thrombopoietin levels are decreased in 
patients with severe fibrosis 38 it may contribute to the interaction between GRO levels and 
platelet counts.
The observed association between plasma GRO levels and ethnicity may at least partially be 
attributed to a previously reported single nucleotide polymorphism (SNP) in the CXCL1 
gene encoding GROα 15. Indeed, Nischalke et al showed that HCV-infected patients 
carrying the A allele of SNP rs4074 had higher serum levels of GROα. Moreover, 
population genotyping data show that the A allele is much more prevalent in African-
Americans (90 %) as opposed to Caucasians (40 %) 16 and is thus a likely explanation for 
the ethnicity-related differences in plasma GRO levels observed in our study. Interestingly, 
the effect of the rs4074 A allele on GROα serum levels was only seen in HCV-infected 
patients but not in healthy individuals 15. This may be due to the HCV antigen-induced 
secretion of GROα, which was also more pronounced in cells from patients with the rs4074 
AA genotype 15. The association of GRO plasma levels with both ethnicity and fibrosis 
might suggest a role for GRO to explain the decreased rate of liver fibrosis in African-
American patients as compared to Caucasian patients 8, 9.
Our finding that GROα is upregulated in response to pegIFN/RBV treatment in Caucasians - 
but not in African-Americans - is intriguing. Although GRO is not known to be an 
interferon-stimulated gene, other proteins induced by interferon treatment might be 
responsible for the effect seen in Caucasian patients. One possibility is thrombopoietin, 
since increased levels of this protein have been described during treatment of HCV-infected 
patients with interferon-α and RBV 39, 40. Thrombopoietin can potentiate GROα release 
from the platelet precursor megakaryocytes 36. Whereas this could explain the increased 
GROα levels in response to pegIFN/RBV treatment in Caucasians, the lack of increased 
GROα levels in African-Americans is less clear. Possibly, the already high pre-treatment 
GROα levels in the latter patients may make it impossible to further increase above the 
maximum expression level. As the change in plasma GROα levels in response to 
pegIFN/RBV treatment is not associated with therapy outcome, it cannot explain the 
discrepancy in response outcome between African-American and Caucasian HCV-infected 
patients. Our results might suggest that increased GRO levels observed during treatment, in 
particular in patients with low baseline GRO levels, are indicative for an improvement in 
liver disease. Future studies that prospectively assess pre- and post-treatment GRO levels in 
association with fibrosis progression during and after therapy are needed to further 
investigate the potential value of GRO as a biomarker in liver disease.
In conclusion, we have identified plasma GRO as a novel chemokine that is associated with 
severity of liver fibrosis. The higher peripheral GRO levels in patients with less severe liver 
fibrosis suggest a protective role for GRO against liver fibrosis. The association of 
peripheral GRO levels with platelet count and ethnicity further adds to the understanding of 
GRO in relation to fibrosis in chronically HCV-infected patients. Complementary functional 
studies on GRO will be needed to further elucidate underlying biological mechanisms.
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Boxplots of plasma levels for the chemokines (A) IP-10, (B) GRO and (C) IL-8, which were 
significantly associated with severe fibrosis. Chemokine data are shown for patients 
stratified according to ISHAK fibrosis score: 0 (n=40), 1–2 (n=202), 3–4 (n=112) and 5–6 
(n=29). P-values were derived by the Tukey’s honest significance test. *<0.05, **<0.01, 
***<0.001. Comparisons without a significant difference (p>0.05) are not shown.
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Correlation between plasma levels of GRO and platelet count at baseline. Caucasian (CA) 
patients are shown as unfilled diamonds and African-American (AA) patients as filled 
circles. Linear regressions with 95% confidence intervals are shown as a dashed line for 
Caucasians (p=1.4×10−18) and a solid line for African-Americans (p=2×10−06).
Johansson et al. Page 13














GROα plasma levels at baseline, week 4 and week 12 after start of pegIFN/RBV treatment 
grouped according to ethnicity. Each line represents one individual patient’s GROα levels 
over time. The thick black lines show the mean for each ethnic group. P-values were 
generated by pairwised student’s t-test. Comparisons without a significant difference 
(p>0.05) are not shown.
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Table 1
Patient characteristics
Characteristics Whole cohort (n=386) Sub cohort for several time points (n=99)
Ethnicity Caucasian, n (%) 197 (51) 48 (48.5)
Gender Female, n (%) 135 (35) 41 (41.4)
Age (years) mean (range) 47.8 (23–70) 47.8 (30–64)
SVR status SVR, n (%) 157 (40.7) 49 (49.5)
IL28B genotype CC, n (%) 89 (30) 15 (19)
CT, n (%) 149 (50.2) 48 (60.8)
TT, n (%) 59 (19.9) 16 (20.3)
HCV RNA log10 (IU/ml) mean (range) 6.3 (3.1–7.7) 6.3 (3.6–7.4)
Platelet count (103 cells/mm3) mean (range) 214.8 (60–489) 214.4 (70–489)
Alanine transaminase (ALT) (IU/L) mean (range) 90.9 (14–508) 88.1 (21–409)
Total bilirubin (mg/dl) mean (range) 0.70 (0.1–2.9) 0.75 (0.1–2.9)
Albumin (g/dl) mean (range) 4.1 (2.3–5) 4.1 (2.9–4.8)
Hemoglobin (g/dl) mean (range) 14.6 (10.7–18) 14.5 (10.8–17.8)
Ferritin (mg/dl) mean (range) 279.8 (5.4–1860) 314.6 (20.1–1860)
ISHAK fibrosis score ≥3 n (%) 141 (36.7) 40 (40.4)
HAI inflammation >8 n (%) 183 (47.7) 46 (46.5)
median (range) 8 (2–14) 8 (2–14)
Steatosis 5≥% n (%) 129 (33.6) 38 (38.4)
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Table 2
Univariate analysis of non-invasive parameters associated with ISHAK fibrosis score <3 or ≥3
Variable Estimate (confidence interval) p-value
Platelet count 52.80 (39.36 : 66.24) 3.63E-12*
ALT• −0.56 (−0.76 : −0.37) 9.19E-07*
Age −3.93 (−5.45 : −2.42) 1.24E-05*
IP-10• −0.47 (−0.68 : −0.26) 3.36E-04*
GRO• 0.48 (0.27 : 0.70) 3.78E-04*
Bilirubin −0.17 (−0.25 : −0.09) 4.03E-04*
Ferritin• −0.63 (−0.93 : −0.33) 1.23E-03*
IL-8• −0.55 (−0.84 : −0.26) 5.34E-03*
I-TAC• −0.30 (−0.52 : −0.09) 1.41E-01
Albumin 0.11 (0.03 : 0.20) 2.50E-01
MIG• −0.21 (−0.40 : −0.02) 6.11E-01
IL-29• −0.25 (−0.47 : −0.02) 6.74E-01
SVR status (SVR or non-SVR) −0.09 (−0.19 : 0.01) 1.00E+00
Hemoglobin −0.18 (−0.45 : 0.10) 1.00E+00
Hematocrit −0.42 (−1.19 : 0.35) 1.00E+00
MIP-1β• 0.18 (−0.15 : 0.51) 1.00E+00
SDF-1α/β• 0.10 (−0.10 : 0.30) 1.00E+00
HCV RNA level• −0.08 (−0.22 : 0.07) 1.00E+00
Gender (F or M) 0.05 (−0.05 : 0.15) 1.00E+00
Ethnicity (AA or CA)† 0.05 (−0.05 : 0.16) 1.00E+00
Triglycerides• −0.06 (−0.21 : 0.10) 1.00E+00
IL-18• −0.06 (−0.31 : 0.18) 1.00E+00
IL28b genotype (CC or CT/TT) −0.01 (−0.12 : 0.10) 1.00E+00
Estimates reflect differences between low compared to high ISHAK score groups and indicate either difference in means (for the continuous 
variables) or differences in proportions (for categorical variables). P-values are derived from t-tests or Chi-square tests for continuous and 
categorical variables, respectively.
*
p-value <0.01, adjusted for multiple comparisons by Bonferroni correction
•
data log-transformed before statistical data analysis
†
AA=African-American, CA=Caucasian
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Table 3
Univariate analysis of liver disease variables associated with plasma levels of GRO
Analyte Estimate (confidence interval) p-value
Ethnicity (AA or CA)† −1.21 (−1.39 : −1.04) 4.31E-33*
Platelet count 0.006 (0.005 : 0.008) 3.96E-15*
ALT• −0.35 (−0.46 : −0.24) 7.63E-09*
Bilirubin −0.72 (−1.02 : −0.43) 3.16E-05*
ISHAK (< or ≥ 3) −0.48 (−0.70 : −0.27) 2.55E-04*
HAI (≤ or > 8) −0.46 (−0.66 : −0.25) 4.14E-04*
Hemoglobin −0.16 (−0.24 : −0.09) 7.95E-04*
IL28B genotype (CC or CT/TT) 0.44 (0.18 : 0.69) 1.46E-02
Steatosis (< or ≥ 5%) −0.31 (−0.54 : −0.09) 1.15E-01
Hematocrit −0.04 (−0.07: −0.01) 1.47E-01
Triglycerides• −0.13 (−0.28 : 0.02) 1.00E+00
HCV RNA level• −0.10 (−0.25 : 0.04) 1.00E+00
Gender (F or M) −0.14 (−0.36 : 0.09) 1.00E+00
Ferritin• −0.03 (−0.11 : 0.04) 1.00E+00
SVR status (SVR or non-SVR) −0.09 (−0.31 : 0.12) 1.00E+00
Albumin −0.08 (−0.41 : 0.26) 1.00E+00
Age −0.003 (−0.016 : 0.011) 1.00E+00
Estimate is the coefficient derived from a linear model
*
p-value <0.01, adjusted for multiple comparisons by Bonferroni correction
•
data log-transformed before statistical data analysis
†
AA=African-American, CA=Caucasian
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